First National Bank of Omaha Invests $12.55 Million in Zimmer Biomet Holdings, Inc. $ZBH

First National Bank of Omaha purchased a new stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the second quarter, Holdings Channel.com reports. The institutional investor purchased 140,635 shares of the medical equipment provider’s stock, valued at approximately $12,552,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. DV Equities LLC purchased a new stake in shares of Zimmer Biomet during the 4th quarter worth about $25,000. Monetary Solutions Ltd bought a new position in shares of Zimmer Biomet in the 4th quarter valued at approximately $30,000. Gen Wealth Partners Inc acquired a new stake in Zimmer Biomet in the 4th quarter worth approximately $31,000. Elevation Wealth Partners LLC lifted its holdings in Zimmer Biomet by 145.9% in the 2nd quarter. Elevation Wealth Partners LLC now owns 386 shares of the medical equipment provider’s stock worth $33,000 after purchasing an additional 229 shares during the last quarter. Finally, Cornerstone Financial Management LLC bought a new stake in Zimmer Biomet during the fourth quarter worth approximately $37,000. 88.89% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Zimmer Biomet

In related news, insider Sang Yi sold 5,000 shares of the stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $82.64, for a total transaction of $413,200.00. Following the sale, the insider directly owned 27,251 shares in the company, valued at $2,252,022.64. This represents a 15.50% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.28% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on ZBH shares. Zacks Research cut shares of Zimmer Biomet from a “hold” rating to a “strong sell” rating in a research note on Monday, July 27th. Royal Bank Of Canada lifted their target price on shares of Zimmer Biomet from $101.00 to $110.00 and gave the stock an “outperform” rating in a report on Thursday, August 6th. Canaccord Genuity Group upped their price target on shares of Zimmer Biomet from $83.00 to $100.00 and gave the company a “hold” rating in a report on Monday, August 10th. BMO Capital Markets reiterated a “market perform” rating and issued a $96.00 price objective on shares of Zimmer Biomet in a research note on Thursday, August 6th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 29th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have issued a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $104.42.

Zimmer Biomet Stock Up 1.1%

Shares of NYSE:ZBH opened at $99.31 on Wednesday. The company has a market capitalization of $18.94 billion, a PE ratio of 24.16, a P/E/G ratio of 3.20 and a beta of 0.45. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.94 and a current ratio of 1.69. The company’s fifty day moving average is $91.91 and its 200-day moving average is $90.74. Zimmer Biomet Holdings, Inc. has a 52 week low of $79.12 and a 52 week high of $108.29.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.01 by $0.06. The firm had revenue of $2.18 billion during the quarter, compared to the consensus estimate of $2.13 billion. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The firm’s quarterly revenue was up 4.8% on a year-over-year basis. During the same period last year, the firm posted $2.07 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.53 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, July 31st. Stockholders of record on Thursday, June 25th were issued a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 1.0%. The ex-dividend date of this dividend was Thursday, June 25th. Zimmer Biomet’s payout ratio is presently 23.36%.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.